Business
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Auto-renewing Master Services Agreement engages Biomerica’s integrated development and manufacturing platform, reflecting the Company’s CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS programIRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into a Master Services Agreement (MSA) with a confidential life sci
About this update from Biomerica, Inc.
[{"type":"image","alt":"Biomerica, Inc.","displaySize":"","headline":null,"caption":"Biomerica, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":232,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/evYfew2KAhA6kb7f5nbo3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcx/https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca","width":232,"height":39},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/evYfew2KAhA6kb7f5nbo3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcx/https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca","width":232,"height":39}},"lazy":false},{"type":"text","content":"Auto-renewing Master Services Agreement engages Biomerica’s integrated development and manufacturing platform, reflecting the Company’s CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS program","length":237,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into a Master Services Agreement (MSA) with a confidential life sciences company to develop proprietary in vitro diagnostic (IVD) assays. The engagement carries an initial contract development target fee of over $1.75 million, to be earned across multiple Statements of Work (SOWs) under the MSA. Biomerica was chosen following a competitive evaluation in which multiple CDMO organizations were assessed.","length":600,"tagName":"p"},{"type":"text","content":"The MSA establishes an initial three-year term with automatic one-year renewals. All development work will be performed at Biomerica’s FDA-licensed, ISO 13485-certified facility in Irvine, California. Revenue will be recognized on a milestone-completion basis as individual SOW deliverables are accepted.","length":304,"tagName":"p"},{"type":"text","content":"CDMO STRATEGY AND REVENUE CONTEXT","length":33,"tagName":"p"},{"type":"text","content":"This CDMO engagement is a direct expression of the same ELISA-based assay development expertise that underpins Biomerica’s own inFoods® IBS technology platform — using capabilities built and refined over more than 40 years. The Company is not pi...